• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Premature Immune Aging Might Be Driver Of Rheumatoid Arthritis

By Dennis Thompson HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 10, 2025.

WEDNESDAY, Sept. 10, 2025 — Rheumatoid arthritis might be caused in part by a prematurely aging immune system, a new study says.

Researchers found that people with joint pain and arthritis exhibited signs of accelerated immune aging, according to findings published recently in the journal eBioMedicine.

This suggests that immune aging might play a direct role in the development of rheumatoid arthritis, an autoimmune disorder that occurs when the immune system attacks a person’s joints, researchers said.

“We’ve discovered that immune aging isn’t just a consequence of rheumatoid arthritis — it may be a driver of the disease itself,” senior researcher Niharika Duggal, an associate professor of immune aging at the University of Birmingham in the U.K., said in a news release.

For the study, researchers analyzed the health of 224 people. Of those, 69 were healthy controls and the rest at different stages in the development of rheumatoid arthritis.

Blood test results found lower levels of T-cells — white blood cells that help identify and attack viruses and bacteria — among patients with early joint symptoms. These patients also had reduced production of fresh T-cells from their thymus gland.

A comprehensive score of immune status called IMM-AGE also reflected accelerated immune aging in people prior to their diagnosis for rheumatoid arthritis, researchers said.

“We found that people in the early stages of rheumatoid arthritis — i.e. before a clinical diagnosis — show signs of faster immune system aging,” Duggal said.

Researchers found even more advanced signs of immune aging among patients following their formal diagnosis with rheumatoid arthritis, including deteriorating T-cells and broader signs of inflammation, results show.

This opens up a potential opportunity for heading off rheumatoid arthritis, Duggal said.

“These findings suggest we might be able to intercept the disease development in at-risk individuals and prevent it from developing by using treatments that slow aging, such as boosting the body’s natural process for clearing out damaged cells,” Duggal said.

Future study could focus on whether existing drugs could counter premature aging and slow or halt the progression of rheumatoid arthritis in people at high risk for the condition, researchers said.

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted September 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.